Ensysce Biosciences

Ensysce Biosciences has developed an abuse-deterrent opioid technology, to prevent the abuse of oxycodone

Ensysce Biosciences, Inc., is an integrated drug delivery company with a proprietary, novel platform for the pain market. Our near term clinical program will initiated in early 2016 for PF614. PF614 with BIO-MD technology was developed to prevent abuse of oxycodone, a pain medicine. Our BIO-MD platform is a proprietary abuse-resistant opioid prodrug technlogy that has broad potential to address the concurrent challenges of treating patients with chronic pain while reducing prescription opioid abuse. The BIO-MD platform eliminates a patients’ ability to abuse prescription medicines by the non-oral route. The company’s extensive portfolio of BIO-MD products provides the company with numerous partnership and co-development opportunities.